human
coronaviru
caus
diseas
emerg
china
decemb
rapidli
propag
numer
countri
contamin
one
million
peopl
kill
april
antivir
treatment
warrant
contain
epidem
sever
candid
alreadi
investig
includ
type
interferon
ifni
martinez
belhadi
et
al
inde
context
emerg
viral
infect
ifni
often
evalu
usual
combin
drug
specif
treatment
develop
due
unspecif
antivir
effect
gao
et
al
loutfi
et
al
omrani
et
al
aim
review
evid
support
evalu
treatment
coronavirus
discuss
potenti
type
interferon
ifni
design
group
cytokin
compris
ubiquit
subtyp
subdivid
sever
isoform
well
subtyp
samuel
secret
variou
cell
type
notabl
plasmacytoid
dendrit
cell
upon
recognit
viral
compon
pattern
recognit
receptor
prr
liu
ifni
thu
among
first
cytokin
produc
viral
infect
recogn
ifnar
receptor
present
plasma
membran
cell
type
interferon
fixat
ifnar
induc
phosphoryl
transcript
factor
reloc
nucleu
activ
interferonstimul
gene
isg
isg
involv
inflamm
signal
immunomodul
interfer
viral
replic
spread
sever
mechan
slowdown
cell
metabol
secret
cytokin
promot
activ
adapt
immun
isg
includ
prr
sensit
cell
pathogen
protein
decreas
membran
fluiditi
prevent
viral
egress
membran
fusion
antivir
specif
inhibit
one
step
viral
cycl
schneider
et
al
totura
baric
ifni
thu
play
major
role
antivir
immun
immunomodulatori
properti
ifni
use
treatment
numer
diseas
exampl
subcutan
inject
use
year
treatment
patient
multipl
sclerosi
role
treatment
multipl
sclerosi
still
debat
like
result
partli
downregul
major
histocompat
complex
mhc
class
ii
express
antigenpres
cell
induct
secret
inhibit
tcell
migrat
jakimovski
et
al
merscov
sarscov
coronavirus
close
link
present
similar
properti
despit
differ
epidemiolog
patholog
sever
protein
lai
et
al
ifni
treatment
studi
merscov
sarscov
review
stockman
et
al
numer
experi
vitro
vivo
combin
lopinavir
ritonavir
chan
et
al
sheahan
et
al
ribavirin
chen
et
al
morgenstern
et
al
omrani
et
al
remdesivir
http
receiv
march
accept
april
corticosteroid
loutfi
et
al
sainz
et
al
scagnolari
et
al
systemat
rel
effici
vitro
succeed
certain
anim
model
chan
et
al
gener
fail
significantli
improv
diseas
human
stockman
et
al
exampl
combin
lopinavirritonavir
merscov
improv
pulmonari
function
significantli
reduc
viru
replic
lung
patholog
sever
sheahan
et
al
combin
ribavirin
delay
mortal
without
decreas
long
run
omrani
et
al
similarli
combin
ribavirin
gave
excel
result
rhesu
macaqu
falzarano
et
al
inconclus
human
arabi
et
al
lack
signific
diseas
improv
ifni
treatment
numer
studi
explain
mechan
inhibit
ifn
signal
pathway
use
merscov
sarscov
limit
number
patient
anim
use
studi
difficulti
deciph
whether
diseas
improv
caus
ifni
drug
use
combin
addit
result
often
differ
substanti
studi
inconsist
experiment
set
clinic
condit
stockman
et
al
exampl
studi
sarscov
reveal
posit
effect
ifni
treatment
loutfi
et
al
anoth
studi
larger
cohort
detect
signific
effect
zhao
et
al
also
propos
interferon
effici
patient
lack
comorbid
altawfiq
et
al
shalhoub
et
al
subtyp
divers
could
anoth
explan
inconsist
studi
repeatedli
shown
potent
inhibitor
coronavirus
scagnolari
et
al
stockman
et
al
depend
studi
potent
ifni
subtyp
inhibit
sarscov
hensley
et
al
merscov
chan
et
al
dong
et
al
hart
et
al
consequ
appear
relev
interferon
treat
coronaviru
infect
fact
relat
protect
activ
lung
upregul
cluster
differenti
pulmonari
endotheli
cell
result
secret
antiinflammatori
adenosin
mainten
endotheli
barrier
function
process
explain
clinic
data
indic
reduct
vascular
leakag
acut
respiratori
distress
syndrom
ard
treatment
bellingan
et
al
howev
effect
insuffici
decreas
ard
mortal
ranieri
et
al
suggest
vivo
studi
mice
time
ifni
administr
play
crucial
role
posit
effect
observ
ifni
administ
shortli
infect
ifni
fail
inhibit
viral
replic
sideeffect
administ
later
channappanavar
et
al
follow
studi
show
effici
lopinavirritonavir
merscov
marmoset
chan
et
al
combin
inject
intraven
lopinavirritonavir
current
investig
clinic
trial
saudi
arabia
arabi
et
al
knowledg
clinic
trial
merscov
knowledg
gain
experi
ifni
treatment
sarscov
merscov
valuabl
select
potenti
treatment
sarscov
merscov
abl
disrupt
interferon
signal
pathway
exampl
protein
sarscov
disrupt
karyopherin
transport
kopeckybromberg
et
al
consequ
inhibit
import
nucleu
transcript
factor
result
interferon
respons
similarli
protein
sarscov
inhibit
phosphoryl
protein
involv
activ
ifn
express
howev
protein
truncat
lokugamag
et
al
may
lost
antiinterferon
function
could
explain
display
vitro
substanti
sensit
lokugamag
et
al
although
replic
entir
suppress
interferon
viral
titer
decreas
sever
order
magnitud
substanti
sensit
ifni
sarscov
suggest
ifni
treatment
least
effect
former
latter
support
hypothesi
shown
spray
reduc
infect
rate
shen
yang
studi
show
ifni
use
prophylaxi
confirm
vitro
efficaci
interferon
pretreat
viru
lokugamag
et
al
replic
merscov
sheahan
et
al
sarscov
menacheri
et
al
thiel
weber
report
indiffer
ifni
prophylaxi
data
present
ifni
might
safe
effici
treatment
knowledg
acquir
studi
merscov
sarscov
would
critic
asset
perspect
exampl
indic
relev
interferon
subtyp
ifni
administ
earli
possibl
optim
antivir
therapi
avoid
advers
event
channappanavar
et
al
furthermor
patholog
mainli
consist
pulmonari
lesion
present
similar
characterist
interferonopathi
may
suggest
induc
excess
ifni
mediat
antivir
respons
lead
tissu
damag
ifni
treatment
limit
earli
phase
infect
hypothesi
confirm
suggest
siddiqi
mehra
earli
clinic
data
show
inflammatori
biomark
associ
increas
mortal
zhou
et
al
late
phase
even
possibl
antiinterferon
drug
use
mitig
patholog
china
guidelin
treatment
recommend
administ
million
u
vapor
inhal
twice
day
patient
combin
ribavirin
dong
et
al
lu
clinic
trial
recent
regist
evalu
combin
lopinavirritonavir
combin
lopinavirritonavir
ribavirin
administ
subcutan
treatment
administr
vapor
inhal
current
perform
china
offer
advantag
target
specif
respiratori
tract
howev
best
knowledg
pharmacodynam
pharmacokinet
mode
administr
never
assess
contrari
intraven
subcutan
mode
administr
welldescrib
alreadi
proven
safe
sever
clinic
trial
similar
pharmacodynam
pharmacokinet
mager
jusko
combin
ifni
lopinavirritonavir
ribavirin
remdesivir
could
improv
efficaci
effici
combin
observ
vitro
coronavirus
sheahan
et
al
might
also
relev
evalu
type
iii
ifn
treatment
lokugamag
et
al
protect
effect
interferon
type
respiratori
tract
subcutan
combin
lopinavirritonavir
compar
lopinavirritonavir
alon
hydroxychloroquin
remdesivir
discoveri
trial
first
clinic
trial
solidar
consortium
clinic
trial
conclus
may
account
safe
easi
upscal
treatment
earli
stage
infect
similar
treatment
mix
effici
merscov
sarscov
virus
vitro
studi
suggest
could
substanti
sensit
ifni
coronavirus
current
lack
anim
model
prevent
clinic
evalu
ifni
treatment
sinc
safeti
alreadi
assess
numer
independ
clinic
trial
public
data
ifnbas
treatment
perform
china
earli
expect
near
futur
give
accur
inform
relev
therapi
none
e
sallard
et
al
antivir
research
